Pedal and puzzle: new home therapy aims to stall dementia in Parkinson's

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * PD diagnosis confirmed by a neurologist * PD diagnosis at least for one year * Age between 51-80 years * German as their mother tongue * Diagnosis of PD-MCI according to the Level II criteria of the Movement Disorder Society * Cognitive ADL impairment as defined by the FAQ quotient * An informant who has given consent to provide information about the participant's activities of daily living (ADLs) and who lives in the participant's home. * Access to a WIFI Network at home * Unimpaired or corrected vision and hearing * Appropriate text comprehension and reading ability * Ability to communicate well with the investigator, to understand and comply with the requirements of the study * Provide written informed consent to participate in the study and understand the right to withdraw consent at any time without prejudice to future medical care Exclusion Criteria: * Diagnosis of PDD * Intake of anti-dementia drugs * Deep brain stimulation * History of brain disease other than PD (e.g. head trauma, stroke, encephalitis) also including muscular diseases (e.g. myestenia gravis or myopathy) * Pre-existing condition that limits limb movement (e.g. muscular injuries, knee and hip disorders * severe cardiovascular diseases with heart failure * severe respiratory diseases (e.g. asthma and lung disease) * severe other accompanying illnesses with impairment of lung function * renal insufficiency * acute stage of infectious disease * acute stage of cancer * other disease with pronounced physical weakness * History of brain disease other than PD, e.g., head trauma, stroke, encephalitis * Alcohol, medication, or drug dependency or abuse (except for nicotine) * Signs of severe depression indicated by either the 15 item version Geriatric Depression Scale (≥ 5 points) * Acute psychosis * Any disability or issues that may prevent the subject from completing the informed consent form or other study requirements * Other neurodegenerative disease which renders the subject unable to communicate well with the investigator or to understand and comply with the requirements of the study * Participation in any clinical investigation of a new compound or therapy within 4 weeks prior to baseline visit, and any other limitation of participation based on local regulations